enGene (NASDAQ:ENGN) Trading Up 5.9%

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) traded up 5.9% during trading on Friday . The company traded as high as $15.00 and last traded at $15.00. 5,384 shares were traded during mid-day trading, a decline of 88% from the average session volume of 43,121 shares. The stock had previously closed at $14.17.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. UBS Group assumed coverage on enGene in a research note on Thursday, March 28th. They issued a "buy" rating and a $37.00 target price for the company. Morgan Stanley initiated coverage on enGene in a research report on Friday, March 8th. They issued an "overweight" rating and a $40.00 price target on the stock. SVB Leerink initiated coverage on enGene in a research report on Tuesday, February 20th. They issued an "outperform" rating and a $31.00 price target on the stock. Leerink Partnrs reiterated an "outperform" rating on shares of enGene in a research report on Tuesday, February 20th. Finally, Guggenheim assumed coverage on enGene in a research report on Monday. They issued a "buy" rating and a $34.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $35.50.

enGene Stock Up 4.8 %

The company's 50 day simple moving average is $15.83.

Institutional Investors Weigh In On enGene

A number of hedge funds have recently modified their holdings of the business. Fcpm Iii Services B.V. bought a new position in shares of enGene during the fourth quarter worth about $80,097,000. Goldman Sachs Group Inc. bought a new position in shares of enGene during the fourth quarter worth about $346,000. Blue Owl Capital Holdings LP bought a new position in shares of enGene during the fourth quarter worth about $11,397,000. Omega Fund Management LLC bought a new position in shares of enGene during the fourth quarter worth about $10,441,000. Finally, BVF Inc. IL bought a new position in shares of enGene during the fourth quarter worth about $20,777,000. Institutional investors and hedge funds own 64.16% of the company's stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.